#LegendCapital #PortfolioNews Our portfolio company Innovent Biologics’ IBI363, a PD-1/IL-2 bispecific antibody, has entered its first registrational study. Developed to enhance immune responses against less immunogenic tumors, including mucosal and acral melanoma, IBI363 has demonstrated promising efficacy and a manageable safety profile in early trials. This study marks a significant step in evaluating its therapeutic potential and broadening treatment options for melanoma patients. Innovent continues to drive innovation in immunotherapy, advancing new treatment options for challenging cancers. #Oncology #Melanoma
Innovent's first-in-class PD-1/IL-2 bispecific antibody (R&D: IBI363) has entered its first registrational study—a major breakthrough in the fight against “cold tumors” like mucosal and acral melanoma. With promising efficacy and a manageable safety profile, the trial aims to establish IBI363 as a next-generation immuno-oncology therapy, bringing new hope for patients and potentially transforming treatment outcomes worldwide. https://lnkd.in/gFJ8QSxX #InnoventBiologics #Oncology #melanoma